The company operates Hotel Revival, a 3-star hotel in Vadodara, Gujarat, and manages wholesale and retail trade of foreign liquor and wine under state-issued licenses.
The company lacks a durable moat, as evidenced by an average ROCE of 1.2% and negative net margins. While it holds specific liquor licenses in a restricted state, these do not translate into pricing power or superior returns, and the business remains a small-scale commodity hospitality provider.
Capital allocation is poor, characterized by reinvestment into hotel renovations that have not yet yielded positive returns, and a reliance on unsecured loans from the Managing Director to sustain operations. No dividends have been paid, and the company remains in a weak liquidity position with low interest coverage.
The company's demise was driven by its inability to generate returns above its cost of capital, as the renovations failed to translate into pricing power or occupancy gains. The reliance on unsecured loans from the Managing Director created a debt trap where meager cash flows were consumed by interest payments, leaving the business unable to modernize. Eventually, the lack of scale and the commodity nature of the hospitality offering led to a liquidity crunch, forcing a fire sale of assets to settle related-party obligations and leaving minority shareholders with pennies on the dollar.
RichFakir rates Lords Ishwar Hotels Ltd's business quality as poor — 14/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Lords Ishwar Hotels Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Lords Ishwar Hotels Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Lords Ishwar Hotels Ltd's fair value is about ₹7 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →